Jung, O., Soto, A., Wolfe, A. L., Mahajan, S. S. (2025). Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity. PLoS ONE. https://doi.org/10.1371/journal.pone.0329946